Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Enterprise Value (2019 - 2026)

C4 Therapeutics has reported Enterprise Value over the past 8 years, most recently at -$235.7 million for Q1 2026.

  • For Q1 2026, Enterprise Value fell 9.57% year-over-year to -$235.7 million; the TTM value through Mar 2026 reached -$235.7 million, down 9.57%, while the annual FY2025 figure was -$248.5 million, 1.48% down from the prior year.
  • Enterprise Value for Q1 2026 was -$235.7 million at C4 Therapeutics, up from -$248.5 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$191.9 million in Q3 2025 and troughed at -$313.7 million in Q3 2022.
  • A 5-year average of -$254.4 million and a median of -$255.6 million in 2024 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: soared 33.94% in 2022 and later decreased 18.04% in 2024.
  • Year by year, Enterprise Value stood at -$276.2 million in 2022, then grew by 8.14% to -$253.7 million in 2023, then grew by 3.46% to -$244.9 million in 2024, then dropped by 1.48% to -$248.5 million in 2025, then grew by 5.18% to -$235.7 million in 2026.
  • Business Quant data shows Enterprise Value for CCCC at -$235.7 million in Q1 2026, -$248.5 million in Q4 2025, and -$191.9 million in Q3 2025.